Allstocks.com's Bulletin Board Post New Topic  New Poll  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » Micro Penny Stocks, Penny Stocks $0.10 & Under » KKUR.......news

 - UBBFriend: Email this page to someone!    
Author Topic: KKUR.......news
Hot-Pepper
Member


Member Rated:
4
Icon 1 posted      Profile for Hot-Pepper     Send New Private Message       Edit/Delete Post   Reply With Quote 
ChromoCure Announces Mayo Clinic Research Confirms Its Technology and Chromosomal Basis of CancerFont size: A | A | A8:01 AM ET 1/5/10 | Market Wire
ChromoCure, Inc. (PINKSHEETS: KKUR) is pleased to announce the basis for the Company's technology confirmed by recent Mayo Clinic researchers. Their findings, which appear in the current issue of the journal Cancer Cell, along with an independent commentary on the discovery, end a major controversy in the field of cancer research as to whether aneuploidy is a cause or a consequence of cancer and further proves the aneuploidy basis of cancer.

This recent publication enhances the company's international activities to promote its cancer detection system and related technology through its ChromoCure Cancer Research & Diagnosis Centers program. The research further confirms the chromosomal theory of cancer and immediately establishes the company's technology in the forefront of both cancer detection and research.

ChromoCure's proprietary CS200 Chromosomal Scanner system and related technology is specifically designed to target the unique chromosomal characteristics demonstrated in the Mayo Clinic research. Detecting the unique chromosomal signature of cancer yields an effectively 100% accurate method of detecting all forms of cancer at all stages.

The company's systems detect the single characteristic found in 100% of all cancers at all stages, and never found in normal cells. The company therefore believes its technology detects cancer with an effective 100% specificity and effective 100% accuracy. The Company's technology also objectively measures, with high precision, the level of cancer present and its stage of progression.

About Mayo Clinic

Mayo Clinic is the first and largest integrated, not-for-profit group practice in the world. Doctors from every medical specialty work together to care for patients, joined by common systems and a philosophy of "the needs of the patient come first." More than 3,700 physicians, scientists and researchers, and 50,100 allied health staff work at Mayo Clinic, which has campuses in Rochester, Minn., Jacksonville, Fla. and Scottsdale/Phoenix, Ariz.; and community-based providers in more than 70 locations in southern Minnesota, western Wisconsin and northeast Iowa. These locations treat more than half a million people each year.

About ChromoCure

ChromoCure develops and provides proprietary cancer detection systems. The Company owns its technology and provides its systems on a revenue sharing basis. The Company's proprietary ChromoCure CS200 Chromosomal Scanner system measure the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company believes its technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology superior and will become the gold standard for cancer detection worldwide.

The Company's technology and cancer expertise also suggest non-toxic and non-invasive approaches to cancer therapy and cure research. The Company will release progress reports on these initiatives from time to time.

Safe-Harbor Statement

This release contains statements or projections regarding future performance that is forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.

Contact:
ChromoCure, Inc.
www.ChromoCure.com
info@chromocure.com
Tel 1.775.636.6548


SOURCE: ChromoCure, Inc.

Posts: 602 | From: Minneapolis | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
Hot-Pepper
Member


Member Rated:
4
Icon 1 posted      Profile for Hot-Pepper     Send New Private Message       Edit/Delete Post   Reply With Quote 
This is moving at a faster pace today.
Posts: 602 | From: Minneapolis | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
Hot-Pepper
Member


Member Rated:
4
Icon 1 posted      Profile for Hot-Pepper     Send New Private Message       Edit/Delete Post   Reply With Quote 
The volume so far is 579,979,515.
Posts: 602 | From: Minneapolis | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
Hot-Pepper
Member


Member Rated:
4
Icon 1 posted      Profile for Hot-Pepper     Send New Private Message       Edit/Delete Post   Reply With Quote 
Today's trading ranch has been 0.0003 low and 0.0008 high, and the high figure could change at the rate it is going by the end of the day.
Posts: 602 | From: Minneapolis | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
Love the Market
Member


Member Rated:
4
Icon 1 posted      Profile for Love the Market     Send New Private Message       Edit/Delete Post   Reply With Quote 
HUGE NEWS !! Could run all week! I've been in since last summer at .0023 - I may raise to .005 for 1/3, .01 for 1/3 and hold 1/3 !!
Posts: 2793 | From: Coral Springs, FL, USA | Registered: Aug 2003  |  IP: Logged | Report this post to a Moderator
Hot-Pepper
Member


Member Rated:
4
Icon 1 posted      Profile for Hot-Pepper     Send New Private Message       Edit/Delete Post   Reply With Quote 
I am with you Love the Market.
Posts: 602 | From: Minneapolis | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
Hot-Pepper
Member


Member Rated:
4
Icon 1 posted      Profile for Hot-Pepper     Send New Private Message       Edit/Delete Post   Reply With Quote 
So far this are the statistics :

Snapshot Classic View » Last Price Today’s Change Bid (Size) Ask (Size) Day’s Range Volume Trade
0.0008 +0.0005 (+166.67%) 0.0007 x5,000 0.0008 x5,000 0.0003 - 0.0008 593,666,415

Posts: 602 | From: Minneapolis | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
Hot-Pepper
Member


Member Rated:
4
Icon 1 posted      Profile for Hot-Pepper     Send New Private Message       Edit/Delete Post   Reply With Quote 
Watch out for some hungry profit takers, who would not allow the run to go to our desirable level before harvest.
Posts: 602 | From: Minneapolis | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
Love the Market
Member


Member Rated:
4
Icon 1 posted      Profile for Love the Market     Send New Private Message       Edit/Delete Post   Reply With Quote 
It's already starting to pull back now....
Posts: 2793 | From: Coral Springs, FL, USA | Registered: Aug 2003  |  IP: Logged | Report this post to a Moderator
Hot-Pepper
Member


Member Rated:
4
Icon 1 posted      Profile for Hot-Pepper     Send New Private Message       Edit/Delete Post   Reply With Quote 
It has kicked up again. In my opinion, it could settle at 0.0015 by the end of this week, but that's easy to say as you know. I guess we will see has it ends up this friday.
Posts: 602 | From: Minneapolis | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
Love the Market
Member


Member Rated:
4
Icon 1 posted      Profile for Love the Market     Send New Private Message       Edit/Delete Post   Reply With Quote 
When I bought in last summer (or spring-it's been a while) it shot from .0022 to .003 on nothing of this magnitude. This is HUGE - I hope to see .005 this week - but who knows. The CEO is quite the scammer if you look at his track record. That's why I want to get MOST of my principal out and play with HIS money for a change!! Look at NEOM - HUGE news 4th quarter and it's gone nowhere.... Just because it's a good company doesn't mean it's a good stock - unfortunately. We have the Creep-CEO's and NITE & Co. to thank for that.

Peace and Good Luck!

Posts: 2793 | From: Coral Springs, FL, USA | Registered: Aug 2003  |  IP: Logged | Report this post to a Moderator
Hot-Pepper
Member


Member Rated:
4
Icon 1 posted      Profile for Hot-Pepper     Send New Private Message       Edit/Delete Post   Reply With Quote 
LOve the Market, you hit it on the money with regards to the CEOs. About the stock itself, I remember when I bought shares during last summer too on 08/31/09 at 0.0029 and also on 09/09/09 at 0.0022 and ended up dumping shares at 0.0015 for a big loss, because it was rapidly decending. I decided that I am going to get my money back this time by starting at 0.0003 and 0.0004. I have packed a lot of shares this time and I'm waiting for the payback. I am a little conservative by thinking more around 0.0015 or 0.002 at the most by Friday. If it gets to 0.005 this week as you are predicting then I'll cash in with a smile.
Posts: 602 | From: Minneapolis | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
Love the Market
Member


Member Rated:
4
Icon 1 posted      Profile for Love the Market     Send New Private Message       Edit/Delete Post   Reply With Quote 
Hot - I wasn't predicting .005 for the week - I was HOPING ! LOL

I just read that Mayo didn't even use KKURs scanner on this - they used another companies. It hit .0012 quickly this morning and is already back to .0008-.0009. Total Dilution I'm guessing.

May not even see .002 or .003 again anytime soon. But these penny's are sooooo unpredictable. we've seen totally diluted garbage run for days; and great companies go no where on great news. Go figure! Good Luck pal!

Posts: 2793 | From: Coral Springs, FL, USA | Registered: Aug 2003  |  IP: Logged | Report this post to a Moderator
Hot-Pepper
Member


Member Rated:
4
Icon 1 posted      Profile for Hot-Pepper     Send New Private Message       Edit/Delete Post   Reply With Quote 
Love the Market, you are correct. It maybe total dilution. The volume was hugh. It closed right where it started with no change even though it hit 0.0012 high this morning, then started decending to where it was yesterday. It's cracy. But let see what it will do tomorrow.
Posts: 602 | From: Minneapolis | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
Love the Market
Member


Member Rated:
4
Icon 1 posted      Profile for Love the Market     Send New Private Message       Edit/Delete Post   Reply With Quote 
Continued back down is what it did today....Ugh.
Posts: 2793 | From: Coral Springs, FL, USA | Registered: Aug 2003  |  IP: Logged | Report this post to a Moderator
Hot-Pepper
Member


Member Rated:
4
Icon 1 posted      Profile for Hot-Pepper     Send New Private Message       Edit/Delete Post   Reply With Quote 
ChromoCure, Inc. Announces Major Therapeutics Research ""ProjectBoveri: Find the Cure""

Feb 2, 2010 08:30:20 (ET)


RENO, NV, Feb 02, 2010 (MARKETWIRE via COMTEX) -- ChromoCure, Inc. (PINKSHEETS: KKUR) announced today the launch of a major new research initiative targeting Cancer Therapy and Cure. The Company has realigned its business strategy due to corroboration by recent Medical Research publications that both validated ChromoCure's chromosomal/aneuploidy theory of cancer and immediately established the company's proprietary ChromoSomal Scanner technology in the forefront of both cancer detection and research. The company will announce new partnerships, products, licensing, and laboratory activities based on this research-oriented alignment.

Research has conclusively, and irrefutably demonstrated aneuploidy as a more accurate predictor of cancer than cytological/histological analysis or genetic marker-based diagnostics that are the only other methods in existence today. ChromoCure's proprietary technology and understanding of cancer also suggest non-toxic and non-invasive approaches to cancer therapy and cure research.

The company's technology and research combined with unique insights provided by the chromosomal theory of cancer paves the way for non-invasive and non-toxic solutions to cancer therapeutics and disease eradication. ChromoCure's ChromoSomal Scanner Technologies, encompassing proprietary designs, processes, and algorithms, provides significant advantage in delivering important and significant results in both therapy and cure.

Support by these recent third party medical findings, the Company is calling for a stepped up collaborative approach through its "Project Boveri: Find the Cure" initiative; and is inviting industry, institutions, medical research centers and government to partner in this initiative. The company has already established a special section of its web site dedicated to this project and research outreach. The Company's recently announced diagnostic partnership program with pathologists and diagnostic labs will be incorporated into Project Boveri in order to broaden awareness of the company's technology.

The company will provide cancer detection and progression measurement services using its own equipment to research partners participating in the Project Boveri initiative. "Project Boveri" is named after Theodor Boveri who first described the chromosomal/aneuploidy theory of cancer diagnosis nearly a century ago.

The company will soon announce the details on various collaborative research centers participating in "Project Boveri: Find the Cure".

About ChromoCure

ChromoCure develops and provides proprietary cancer detection systems and technologies. The Company's proprietary ChromoCure CS200 Chromosomal Scanner system has been proven accurate and efficient in the measurement of the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company's detection technology has been proven to have an effective accuracy of 100% for all cancers at all stages. The Company believes its technology will become the worldwide gold standard for cancer detection, progression measurement, and research for both therapy and cure.

Safe-Harbor Statement

This release contains statements or projections regarding future performance that is forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.


ChromoCure, Inc.

www.ChromoCure.com

info@chromocure.com
Tel 1.775.636.654


SOURCE: ChromoCure, Inc.


http://www.ChromoCure.com

mailto:info@chromocure.com

Posts: 602 | From: Minneapolis | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
western acres
Member


Rate Member
Icon 1 posted      Profile for western acres     Send New Private Message       Edit/Delete Post   Reply With Quote 
Hot-Pepper GOOD news
Ameritrade says there are 523.1M shares out. I looked on KKUR's site for this info. Did I miss it? I know you have a good way of getting info. The volumn and the shares sold just look like a large % sold. I am in this one long and really hope it is a GOOOOOD one!
Thanks for any info you have.

Posts: 49 | From: Texas | Registered: Jul 2009  |  IP: Logged | Report this post to a Moderator
Hot Pepper
Member


Rate Member
Icon 1 posted      Profile for Hot Pepper     Send New Private Message       Edit/Delete Post   Reply With Quote 
ChromoCure Rebrands Corporate Image and Realigns Operations toReflect Its Pioneering Role in Cancer Detection, Therapy and Cure

Feb 22, 2010 08:30:41 (ET)


RENO, NV, Feb 22, 2010 (MARKETWIRE via COMTEX) -- ChromoCure, Inc. (PINKSHEETS: KKUR) announced today the official launch of its realigned business strategy and its corporate rebranding. The Company recently announced its accelerated Therapy and Cure initiatives through the launch of Project Boveri: Find the Cure; and the new branding properly reflects its pioneering role in cancer detection, therapy and cure; and its increased research programs and collaborations. Learn more about the company's new branding and initiatives at www.ChromoCure.com .

As recently announced the Company realigned its business strategy due to corroboration by recent Medical Research publications that both validated ChromoCure's chromosomal/aneuploidy theory of cancer and immediately established the company's proprietary ChromoSomal Scanner technology in the forefront of both cancer detection and research.

Research has conclusively, and irrefutably demonstrated aneuploidy as a more accurate predictor of cancer than cytological/histological analysis or genetic marker-based diagnostics that are the only other methods in existence today. ChromoCure's proprietary technology and understanding of cancer also suggest non-toxic and non-invasive approaches to cancer therapy and cure research.

The company's technology and research combined with unique insights provided by the chromosomal theory of cancer paves the way for non-invasive and non-toxic solutions to cancer therapeutics and disease eradication. ChromoCure's ChromoSomal Scanner Technologies, encompassing proprietary designs, processes, and algorithms, provides significant advantage in delivering important and significant results in diagnosis therapy and cure.

Supported by recent third party medical findings, the Company launched its collaborative research approach with its "Project Boveri: Find the Cure" initiative; and is inviting industry, institutions, medical research centers and government to partner in this initiative. The company has already established a special section of its web site dedicated to this project and research outreach. The Company's recently announced diagnostic partnership program with pathologists and diagnostic labs will be incorporated into Project Boveri in order to broaden awareness of the company's technology.

The company will soon announce various collaborative research agreements as well as progress reports on new partnerships, products, licensing, and laboratory activities based on its research-oriented alignment.

About ChromoCure

ChromoCure develops and provides proprietary cancer detection systems and technologies. The Company's proprietary ChromoCure CS200 Chromosomal Scanner system has been proven accurate and efficient in the measurement of the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company's detection technology has been proven to have an effective accuracy of 100% for all cancers at all stages. The Company believes its technology will become the worldwide gold standard for cancer detection, progression measurement, and research for both therapy and cure.

Safe-Harbor Statement

This release contains statements or projections regarding future performance that is forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.


ChromoCure, Inc.

www.ChromoCure.com

info@chromocure.com
Tel 1.775.636.6548


SOURCE: ChromoCure, Inc.


http://www.ChromoCure.com

mailto:info@chromocure.com

Posts: 94 | From: Minneapolis, Mn. 55458 | Registered: Feb 2000  |  IP: Logged | Report this post to a Moderator
Love the Market
Member


Member Rated:
4
Icon 1 posted      Profile for Love the Market     Send New Private Message       Edit/Delete Post   Reply With Quote 
This is a "trading" stock only - Get in and out. I'm stuck holding a ton of it at .0024 or so....Check out the CEO's dubious resume.... and you'll see why. Even when they pump the hell out of it on paid services - it will run a little but crash back in less than an hour nowadays.

I should have gotten out last summer - now I'm a "Stuck".

Good luck.

Posts: 2793 | From: Coral Springs, FL, USA | Registered: Aug 2003  |  IP: Logged | Report this post to a Moderator
Hot Pepper
Member


Rate Member
Icon 1 posted      Profile for Hot Pepper     Send New Private Message       Edit/Delete Post   Reply With Quote 
I agree with you Love the Market. I lsot a liitle last summer, but I got in at 0.0004 last month, I picked up quite a bit of shares last week friday at 0.0002 after cashing in on TPHM, and I plan on cashing in if it ever move to a reasonable level that would allow me to capture what I nlost last summer and some. At this 0.0002 on the asking side, she can only go up or stay where she's at. On the hang side, I should have waiting a few more days for TPHM now that I see where she's at from last Thursday. As you know, had I know always comes last in this business [Smile] .
Posts: 94 | From: Minneapolis, Mn. 55458 | Registered: Feb 2000  |  IP: Logged | Report this post to a Moderator
Hot Pepper
Member


Rate Member
Icon 1 posted      Profile for Hot Pepper     Send New Private Message       Edit/Delete Post   Reply With Quote 
ChromoCure Completes Realignment of Management as First Step inTransition to Cancer Therapy and Cure Research & Development

Mar 1, 2010 13:51:14 (ET)


RENO, NV, Mar 01, 2010 (MARKETWIRE via COMTEX) -- ChromoCure, Inc. (PINKSHEETS: KKUR) announced today the completion of the first major step in its transition to a focused Cancer Therapy and Cure Research & Development organization. The Company recently announced its accelerated Therapy and Cure initiatives through the launch of Project Boveri: Find the Cure; properly reflecting its pioneering role in cancer detection, therapy and cure; and its increased research programs and collaborations.

This major realignment of the Company's business strategy includes the departure of all prior management. The Company will soon announce its new management team with proven credentials to maintain ChromoCure's leadership and pioneering role in Cancer Therapy and Cure initiatives worldwide.

As recently announced the Company had realigned its business strategy due to corroboration by recent Medical Research publications that both validated ChromoCure's chromosomal/aneuploidy theory of cancer and immediately established the company's proprietary Chromosomal Scanner technology in the forefront of both cancer detection and research.

Research has conclusively, and irrefutably demonstrated aneuploidy as a more accurate predictor of cancer than cytological/histological analysis or genetic marker-based diagnostics that are the only other methods in existence today. ChromoCure's proprietary technology and understanding of cancer also suggest non-toxic and non-invasive approaches to cancer therapy and cure research.

The company's technology and research combined with unique insights provided by the chromosomal theory of cancer paves the way for non-invasive and non-toxic solutions to cancer therapeutics and disease eradication. ChromoCure's ChromoSomal Scanner Technologies, encompassing proprietary designs, processes, and algorithms, provides significant advantage in delivering important and significant results in diagnosis therapy and cure.

Support by these recent third party medical findings, the Company is calling for a stepped up collaborative approach through its "Project Boveri: Find the Cure" initiative; and is inviting industry, institutions, medical research centers and government to partner in this initiative. The company has already established a special section of its web site dedicated to this project and research outreach. The Company's recently announced diagnostic partnership program with pathologists and diagnostic labs will be incorporated into Project Boveri in order to broaden awareness of the company's technology.

The company will provide timely updates on new management as well as progress reports on new management appointments; as well as partnerships, products, licensing, and laboratory activities based on this research-oriented alignment.

About ChromoCure ChromoCure develops and provides proprietary cancer detection systems and related therapeutic technologies. The Company's proprietary CS200 Chromosomal Scanner has been proven accurate and efficient in the measurement of the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company's detection technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology will become the worldwide gold standard for cancer detection, progression measurement, and research for both therapy and cure. The Company also applies its technology and knowledge to cancer cure and therapeutics research.

Safe-Harbor Statement This release contains statements or projections regarding future performance that is forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.


ChromoCure, Inc.

www.ChromoCure.com

info@chromocure.com
Tel 1.775.636.6548


SOURCE: ChromoCure, Inc.


http://www.ChromoCure.com

mailto:info@chromocure.com

Posts: 94 | From: Minneapolis, Mn. 55458 | Registered: Feb 2000  |  IP: Logged | Report this post to a Moderator
Hot Pepper
Member


Rate Member
Icon 1 posted      Profile for Hot Pepper     Send New Private Message       Edit/Delete Post   Reply With Quote 
ChromoCure to Begin Live Animal Trials for Clinical Therapeutics Research With University Research ProgramsFont size: A | A | A9:00 AM ET 3/25/10 | Marketwire
ChromoCure, Inc. (PINKSHEETS: KKUR) -- ChromoCure announced today an expansion of its Cancer Research initiatives with Live Animal Therapeutics Research collaboration with selected University Cancer Research Programs.

This Collaborative Research Initiative will be a strategic expansion of the Company's "Project Boveri: Find the Cure," adding the ability to monitor hourly chromosome aneuploidy progression. The company's technology and related research opens the way for non-invasive and non-toxic solutions to cancer therapeutics and disease eradication.

The Company believes its cancer detection and progression measurement capabilities provide unprecedented monitoring and objective measurement of therapeutic research and results.

The Company's focus on cancer research has been validated and further underscored by recent major clinical publications that both validate ChromoCure's chromosomal (aneuploidy) theory of cancer and establish the company's detection approach as the forefront of both cancer detection and research.

The Company's proprietary technology has proven accurate in the measurement of the unique genomic characteristic found in 100% of all cancers and to have an effective accuracy of 100% for all cancers at all stages. ChromoCure's scanner technologies include proprietary designs, processes, and algorithms centered on chromosomal imbalance. They provide the foundation for significant advantages in delivering important results in diagnosis, therapy and cure.

The Company invites University collaboration through its "Project Boveri: Find the Cure" initiative.

The Company will soon announce important additions and changes to its operations and research in the areas of therapeutics and disease eradication.

About ChromoCure

ChromoCure develops and provides proprietary cancer detection systems and related therapeutic technologies. The Company's proprietary CS200 Chromosomal Scanner has been proven accurate and efficient in the measurement of the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company's detection technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology will become the worldwide gold standard for cancer detection, progression measurement, and research for both therapy and cure. The Company also applies its technology and knowledge to cancer cure and therapeutics research.

Safe-Harbor Statement

This release contains statements or projections regarding future performance that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.

ChromoCure, Inc.
www.ChromoCure.com
info@chromocure.com
Tel 1.775.636.6548


SOURCE: ChromoCure, Inc.

http://www.ChromoCure.com
mailto:info@chromocure.com

Posts: 94 | From: Minneapolis, Mn. 55458 | Registered: Feb 2000  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is not enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  New Poll  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2021 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share